EGFR and non-small cell lung carcinoma: RAF is a validated target directly downstream of oncogenic RAS, and SRC is also a validated therapeutic target in CRC, NSCLC and PDAC, where it is hyperactivated and drives cell proliferation and metastasis.22, 23, 24, 25 Accordingly, SRC inhibitors cooperate with drugs that target the EGFR/RAS pathway.26